Candel Therapeutics Dividends and Buybacks
Dividend criteria checks 0/6
Candel Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-5.7%
Buyback Yield
| Total Shareholder Yield | -5.7% |
| Future Dividend Yield | 0% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Candel Therapeutics: Innovative Cancer Therapies, But Short Cash Runway
Jul 01Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer
Apr 15Candel gets European orphan drug designation for brain, spinal cord tumor treatment
Sep 15Candel Therapeutics appoints CFO, chief medical officer
Sep 07Candel Therapeutics: Next-Generation Oncolytic Viral Immunotherapies
Oct 21Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if CADL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CADL's dividend payments have been increasing.
Dividend Yield vs Market
| Candel Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (CADL) | n/a |
| Market Bottom 25% (US) | 1.3% |
| Market Top 25% (US) | 4.2% |
| Industry Average (Biotechs) | 2.3% |
| Analyst forecast (CADL) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate CADL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CADL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate CADL's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CADL has not reported any payouts.